Compare · EXOZ vs GILD
EXOZ vs GILD
Side-by-side comparison of eXoZymes Inc. (EXOZ) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXOZ and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $190.38B, about 4448.0x EXOZ ($42.8M).
- Over the past year, EXOZ is down 69.3% and GILD is up 33.6% - GILD leads by 102.9 points.
- GILD has been more active in the news (4 items in the past 4 weeks vs 3 for EXOZ).
- GILD has more recent analyst coverage (25 ratings vs 0 for EXOZ).
- Company
- eXoZymes Inc.
- Gilead Sciences Inc.
- Price
- $4.00-30.19%
- $157.42+2.51%
- Market cap
- $42.8M
- $190.38B
- 1M return
- -38.46%
- +6.57%
- 1Y return
- -69.25%
- +33.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 3
- 4
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest EXOZ
- SEC Form 8-K filed by eXoZymes Inc.
- SEC Form DEFA14A filed by eXoZymes Inc.
- SEC Form DEF 14A filed by eXoZymes Inc.
- eXoZymes Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Vice President- Finance Nawaz Fouad
- eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
- Chief Executive Officer Heltzen Michael bought $6,405 worth of shares (855 units at $7.49) and was granted 8,841 shares, decreasing direct ownership by 6% to 13,853 units (SEC Form 4)
- Chief Commercial Officer Perriman Damien Alan converted options into 19,612 shares, increasing direct ownership by 221% to 28,499 units (SEC Form 4)
- Chief Scientific Officer Korman Tyler Paz converted options into 32,964 shares, increasing direct ownership by 5% to 762,837 units (SEC Form 4)
- eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
Latest GILD
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)